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Abstract
Background: In addition to caudal subnucleus caudalis (Vc) of the spinal trigeminal complex, recent studies
indicate that the subnuclei interpolaris/caudalis (Vi/Vc) transition zone plays a unique role in processing deep
orofacial nociceptive input. Studies also suggest that glia and inflammatory cytokines contribute to the
development of persistent pain. By systematically comparing the effects of microinjection of the antiinflammatory
cytokine interleukin (IL)-10 and two glial inhibitors, fluorocitrate and minocycline, we tested the hypothesis that
there was a differential involvement of Vi/Vc and caudal Vc structures in deep and cutaneous orofacial pain.
Results: Deep or cutaneous inflammatory hyperalgesia, assessed with von Frey filaments, was induced in rats by
injecting complete Freund's adjuvant (CFA) into the masseter muscle or skin overlying the masseter, respectively.
A unilateral injection of CFA into the masseter or skin induced ipsilateral hyperalgesia that started at 30 min,
peaked at 1 d and lasted for 1-2 weeks. Secondary hyperalgesia on the contralateral site also developed in
masseter-, but not skin-inflamed rats. Focal microinjection of IL-10 (0.006-1 ng), fluorocitrate (1 μg), and
minocycline (0.1-1 μg) into the ventral Vi/Vc significantly attenuated masseter hyperalgesia bilaterally but without
an effect on hyperalgesia after cutaneous inflammation. Injection of the same doses of these agents into the caudal
Vc attenuated ipsilateral hyperalgesia after masseter and skin inflammation, but had no effect on contralateral
hyperalgesia after masseter inflammation. Injection of CFA into the masseter produced significant increases in N-
methyl-D-aspartate (NMDA) receptor NR1 serine 896 phosphorylation and glial fibrillary acidic protein (GFAP)
levels, a marker of reactive astrocytes, in Vi/Vc and caudal Vc. In contrast, cutaneous inflammation only produced
similar increases in the Vc.
Conclusion: These results support the hypothesis that the Vi/Vc transition zone is involved in deep orofacial
injury and suggest that glial inhibition and interruption of the cytokine cascade after inflammation may provide
pain relief.
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Background
Sensory information from the cranial orofacial region is
first relayed in the spinal trigeminal nucleus complex,
which is further divided rostrocaudally into the subnuclei
oralis, interpolaris (Vi) and caudalis (Vc) [1]. It is widely
accepted that nociceptive input from the cranial orofacial
region is initially processed in the Vc [2], which exhibits
lamination and considerable similarity with spinal dorsal
horn and thus is termed the medullary dorsal horn [3].
Advances in our understanding of trigeminal pain
processing have occurred in recent years and attention has
been given to other components of trigeminal nociceptive
pathways beyond the medullary dorsal horn [4-6]. Partic-
ularly, studies have pointed out increased excitability and
sensitization of another region of the spinal trigeminal
complex, the Vi/Vc transition zone. Around the obex level,
the ventral portion of the laminated Vc is replaced by the
caudal Vi that converges with the rostral Vc with imper-
fectly laminated structures, allowing the appearance of the
Vc (mainly dorsal) and Vi (mainly ventral) at the same
coronal plane and thus termed the trigeminal Vi/Vc tran-
sition zone [see [7]]. Most interestingly, a peculiar bilat-
eral neuronal activation in the ventral portion of the Vi/Vc
transition zone, together with unilateral activation in the
caudal Vc, has been observed following orofacial injury
and noxious stimulation [8-14]. Further studies suggest
that the Vi/Vc transition zone is involved in processing
deep orofacial input. Utilizing Fos protein expression as a
marker of neuronal activation, it has been shown that
deep tissue masseter inflammation evokes activity in the
Vi/Vc and caudal Vc regions, whereas after cutaneous
injury, activity is almost entirely limited to the caudal Vc
[11]. While both masseter and cutaneous inputs project to
the caudal Vc, masseter, but not cutaneous, afferents pro-
vide an additional input to the Vi/Vc [7].
Recent studies suggest that glia and inflammatory
cytokines contribute to the development of persistent
pain [15-20]. In the spinal dorsal horn, it has been found
that numerous glial profiles, particularly astrocytic pro-
files, are in apposition with descending serotonergic and
noradrenergic varicosities [21]. Peripheral tissue or nerve
injury induces central nervous system (CNS) glial hyper-
activity, mainly involving astrocytes and microglia
[22,23]. Earlier evidence indicates that spinal astrocytes
are activated after nerve injury [24,25]. Activation of
microglia has been shown to play a critical role in neuro-
pathic pain [23,26-29]. Disrupting glial activation blocks
exaggerated pain responses and activation of glia is suffi-
cient to induce hyperalgesia [30]. Intrathecally adminis-
tered IL-1β, a prototypical proinflammatory cytokine,
produces enhanced spinal dorsal horn nociceptive neuro-
nal responses and behavioral hyperalgesia [31-33]. In
contrast, anti-inflammatory cytokines, such as interleukin
(IL)-10, block the induction of proinflammatory
cytokines and attenuate hyperalgesia [34-36]. Laughlin et
al. [37] demonstrated that IL-10 attenuated intrathecal
dynorphin-induced allodynia. Our recent results have
demonstrated that in association with astroglial activa-
tion, IL-1β is induced in the Vi/Vc transition zone after
masseter inflammation and that the development of oro-
facial hyperalgesia involves signal interactions between
the IL-1 receptor and the N-methyl-D-aspartate (NMDA)
receptor [17].
By systematically comparing the effects of focal microin-
jection of the antiinflammatory cytokine IL-10 and two
glial inhibitors, fluorocitrate and minocycline, the present
study tested the hypothesis that there was differential
involvement of Vi/Vc and caudal Vc structures in deep and
cutaneous orofacial pain. The results show that injection
of IL-10 and glial inhibitors into the Vi/Vc attenuated
masseter but not cutaneous hyperalgesia, while injection
of these agents into the Vc reduced both masseter and
cutaneous hyperalgesia associated with complete Freund's
adjuvant (CFA)-induced inflammation.
Methods
Animals
Male Sprague-Dawley rats were used (280-330 g, Harlan,
Indianapolis). The rats received CFA (0.05 ml, 1:1 oil/
saline suspension, Sigma) into the unilateral masseter
muscle or the skin overlying the masseter muscle under
brief halothane anesthesia to induce inflammation and
hyperalgesia. Saline-injected and naive rats were used as
controls. The selective inflammation of the muscle and
cutaneous tissues was verified with Evans' blue extravasa-
tion as described previously [7]. After injection of CFA
into the masseter muscle, the skin overlying the inflamed
masseter did not show an increase in the dye level com-
pared to the naive rats, whereas the Evans' blue concentra-
tion was increased in the masseter. Injection of CFA into
the skin overlying the masseter muscle led to an increase
in the Evans blue dye level in the skin but not in the deep
masseter muscle. The CFA-injected rats show normal
behavior and levels of activity and the effect of hyperalge-
sia on normal behavior of the animal was minimal
[10,11,38,39]. All experiments were carried out in accord-
ance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals (NIH Publications
No. 80-23) and approved by the University of Maryland
Dental School Institutional Animal Care and Use Com-
mittee. All efforts were made to minimize the number of
animals used and their suffering.
Behavioral testing
All behavioral tests were conducted under blind condi-
tions as described elsewhere [14,40]. A series of calibrated
von Frey filaments were applied to the skin above the
masseter muscle. An active withdrawal of the head fromMolecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
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the probing filament was defined as a response. Each von
Frey filament was applied 5 times at intervals of a few sec.
The response frequencies [(number of responses/number
of stimuli) × 100%] to a range of von Frey filament forces
were determined and a stimulus-response (S-R) curve
plotted. After a non-linear regression analysis, an EF50
value, defined as the von Frey filament force (g) that pro-
duces a 50% response frequency, was derived from the S-
R curve. We used EF50 values as a measure of mechanical
sensitivity. A leftward shift of the S-R curve, resulting in a
reduction of EF50, occurred after inflammation [14,41].
This shift of the curve suggests the presence of mechanical
hyperalgesia and allodynia since there was an increase in
response to suprathreshold stimuli and a decreased
response threshold for nocifensive behavior. Local
anesthesia of the skin site overlying the inflamed masseter
muscle was performed to confirm the validity of the von
Frey method for assessing the mechanical sensitivity of
the masseter muscle after inflammation (see results and
Fig. 1).
Drug administration
For microinjection, a guide cannula (C315G, 26 gauge,
Plastics One, Roanoke, VA) was implanted under anesthe-
sia with 50 mg/kg pentobarbital sodium (i.p) (Fig. 2A).
Animals were securely placed into a stereotaxic device
(Kopf Model 900). A burr hole was drilled and the guide
cannula was lowered into the ventral Vi/Vc transition
Figure 1
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Mechanical hyperalgesia/allodynia induced by injection of  CFA into the right masseter muscle of the rat Figure 1
Mechanical hyperalgesia/allodynia induced by injec-
tion of CFA into the right masseter muscle of the rat. 
The EF50s were derived from the respective stimulus-
response frequency function curves and are plotted against 
time. Note log scales for the ordinate and abscissa. A. Ipsilat-
eral site. Note significant decreases in EF50s at 30 min-7 d 
after CFA injection, indicating inflammatory hyperalgesia/allo-
dynia. B. Contralateral site. There were significant reduc-
tions in EF50s at 180 min-3 d after CFA, indicating the 
development of secondary hyperalgesia after masseter 
inflammation. C. To verify muscle hyperalgesia after injection 
of CFA into the masseter, local anesthesia was induced in the 
masseter or the overlying skin ipsilateral to inflammation by 
bupivacaine (0.75%, 0.1 ml) at 20 min before CFA injection. 
Compared to saline-treated rats (Sal Mass, n = 5), hyperalge-
sia was eliminated when the masseter was anesthetized (Bupi 
Mass, n = 5) and reappeared at 24 h after CFA. Local 
anesthesia of the skin overlying masseter (Bupi Skin, n = 8) 
did not produce a significant effect on the development of 
hyperalgesia. Asterisks in panels A and B denote significant 
differences from the baseline values (*, p < 0.05; **, p < 0.01). 
Pound signs in C indicate significant differences from the 
saline control (Sal Mass) (p < 0.01). (ANOVA with repeated-
measures and post hoc tests).Molecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
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A. Illustration of implantation of the injection cannula into the Vi/Vc region Figure 2
A. Illustration of implantation of the injection cannula into the Vi/Vc region. Left: Horizontal view of a rat skull dia-
gram illustrating the site of cannula implantation (burr hole: 4.7-5.2 mm posterior to lambda) [42]. Note that two screws and a 
patch of cranioplastic cement were used to help secure the cannula. Right: Coronal brain section. The guide cannula was 
inserted into the brainstem site at a 15.75° angle. The tip of the cannula was located in the ventral Vi/Vc transition zone at a 
horizontal plane 9.1 mm ventral to the surface of the skull. B, C. Cresyl violet stained brainstem sections illustrating the site of 
microinjection in the Vi/Vc transition zone (B) and Vc (C) (arrows). Scale bars in B, C = 0.5 mm.Molecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
Page 5 of 18
(page number not for citation purposes)
zone or superficial layers of the caudal Vc by referring to
the rat brain atlas [42]. The guide cannula was then
secured with cranioplastic cement. To prevent clogging of
the guide cannula, a dummy cannula (C315DC, Plastics
One) was inserted and secured in place until the time of
injection. The wound was cleaned with an antiseptic solu-
tion and closed with 4-0 silk sutures. Animals were
allowed to recover for 1 week before further experimenta-
tion. Drugs were injected into the ventral Vi/Vc transition
zone or superficial Vc ipsilateral to inflammation through
a 33-gauge injection cannula (C315I, Plastic One)
inserted through the tip of the guide cannula. The injec-
tion cannula was connected to a 1-μl Hamilton syringe by
polyethylene-10 tubing. All injections (500 nl) were per-
formed by delivering drug or vehicle solutions slowly over
a 2-min period. Animals were perfused with 4% parafor-
maldehyde at the conclusion of the experiment and the
sections of brainstem tissues were stained with cresyl vio-
let for histological verification of the sites of injection.
Brainstem tissue dissection
The rats were anesthetized with halothane and quickly
decapitated. A block of caudal brainstem tissues was cut.
Two tissue blocks, including a 2-mm segment at the level
of the obex and a 2-mm segment at caudal Vc (3-5 mm
caudal to the obex), were dissected. The full length of the
trigeminal Vi/Vc transition zone is enclosed in the rostral
block. The caudal block includes the caudal laminated Vc.
The tissue blocks were then turned coronally and the ven-
tral portions of the transition zone and superficial portion
of the Vc were harvested by taking punches with a 15-
gauge puncture needle.
Reverse transcription polymerase chain reaction (RT-PCR)
The brain stem tissues were dissected and put immedi-
ately into dry ice. Total RNA was extracted after phase sep-
aration, precipitation, and ethanol wash. A 260/280 ratio
of the final RNA solution was no less than 1.6. The first-
strand cDNA was reverse-transcribed in reaction mixture
(20 μl) with the SuperScript III First-Strand Synthesis Sys-
tem for RT-PCR (Invitrogen) (Gibco BRL) and oligo-dT
primers using 3.0 μg of total RNAs at 42°C for 1 hr. The
oligonucleotide primers for PCR reaction were synthe-
sized by The University of Maryland Biopolymer/Genom-
ics Core Facility.
The PCR reaction mixture (50 μl) contained: synthesized
cDNA reverse-transcribed using 0.45 μg of total RNAs, 1 ×
PCR buffer (in mM: 10 Tris-HCl, pH 9.0 at 20°C, 50 KCl,
and 1.5 MgCl2), dCTP, dGTP, dATP and dTTP (0.2 mM
each), 0.2 mM concentration of each set of the 5' and 3'
sequence-specific target primers, recombinant Taq DNA
Polymerase (Invitrogen) (5 units). PCR was performed
after initial denaturation at 94°C for 10 min. The temper-
ature cycle (Robocycler Infinity, Stratagene) was: 94°C/1
min (denaturing), 55°C/1 min (annealing), 72°C/2.5
min (extension). A total of 40 cycles and a final 10 min
extension at 72°C were conducted. The glyceraldehyde
phosphate dehydrogenase (GAPDH) mRNA RT-PCR was
used as an endogenous internal control since its expres-
sion was not regulated by inflammation and manipula-
tion within the design of these experiments [43,44]. To
minimize the substrate competition [45], the primers for
GAPDH cDNA (0.1 mM) were added to the reaction mix-
ture after the first 20 cycles of PCR reaction, and an addi-
tional 20 cycles of amplification were performed. The PCR
amplified fragments were separated on a 2% ethidium
bromide-stained agarose gel. To determine relative expres-
sion levels of each target gene, the intensity of each spe-
cific PCR product band (UN-SCAN-IT gel 5.3, Silk
Scientific Corp.) was normalized to the intensity of the
respective GAPDH band and the ratios were used for
ANOVA. The positive PCR bands were purified (Agarose
Gel DNA Extraction kit, Roche) and sequenced (ABI 373
DNA Sequencer, Perkin Elmer), and the acquired
sequences were verified. Mock RT-PCR reaction controls
were performed by omitting primers, using templates
derived from reverse transcription reactions lacking either
reverse transcriptase or total RNAs. No specific PCR prod-
uct was found in control reactions.
Western blot
The tissues were homogenized in solubilization buffer
(50 mM Tris.HCl, pH8.0; 150 mM NaCl, 1 mM EDTA, 1%
NP40, 0.5% deoxycholic acid, 0.1% SDS, 1 mM Na3VO4,
1 U/ml aprotinin, 20 μg/ml leupetin, 20 μg/ml pepstatin
A). The homogenate was centrifuged at 20,200 × g for 10
min at 4°C. The supernatant was removed. The protein
concentration was determined using a detergent-compat-
ible protein assay with a bovine serum albumin standard.
Each sample contains proteins from one animal. The pro-
teins (50 μg) were separated on a 7.5% SDS-PAGE gel and
blotted to a nitrocellulose membrane (Amersham Bio-
sciences, Arlington Heights, IL). The blots were blocked
with 5% milk in tris-buffered saline (TBS) buffer and then
incubated with the respective antibody. The membrane
was washed with TBS and incubated with anti-goat or
mouse IgG (1:3000, Santa Cruz Biotechnology, Santa
Cruz, CA). The immunoreactivity was detected using
Enhanced Chemiluminescence (ECL, Amersham). The
loading and blotting of the amount of protein was verified
by reprobing the membrane with anti-β-actin antiserum
(Sigma) and with Coomassie blue staining.
Drugs and antibodies
The following drugs and antibodies were purchased from
commercial sources: bupivacaine (Henry Schein, Melville,
NY), IL-10 (PeproTech Inc. Rocky Hill, NJ), fluorocitrate
and minocycline (Sigma, St. Louis, MO), and anti-glialMolecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
Page 6 of 18
(page number not for citation purposes)
fibrillary acidic protein (GFAP) and anti-P-ser896 NR1
antibodies (Millipore-Chemicon, Temecula, CA).
Data analysis
Data are presented as mean ± S.E.M. Statistical compari-
sons were made by the use of ANOVA with Fisher's PLSD
test for post-hoc analysis. For Western blot and RT-PCR
analyses, the ECL-exposed films or gel images were digi-
tized and densitometric quantification of immunoreac-
tive of cDNA bands was carried out using UN-SCAN-IT gel
(ver. 5.3, Silk Scientific Inc., Orem, UT). The relative pro-
tein or mRNA levels were obtained by comparing the
respective specific band to the β-actin or GAPDH control
from the same membrane or gels. The deduced ratios were
further normalized to that of the naive rats on the same
membrane and illustrated as percentage of the naïve con-
trols. ANOVA and the unpaired 2-tailed t-test were used to
determine significant differences. For animals that were
subject to repeated testing, ANOVA with repeated meas-
ures was used with time as a within animal effect. P < 0.05
is considered significant for all cases.
Results
Mechanical hyperalgesia/allodynia associated with 
masseter muscle inflammation
Inflammatory hyperalgesia was induced by a unilateral
injection of an inflammatory agent, CFA, into the right
masseter muscle under brief isoflurane anesthesia. Saline
was used as a control. The mechanical responses to von
Frey filament probing were assessed and stimulus-
response frequency (S-R) curves generated [not shown]
[14,41]. After injection of CFA into the masseter muscle,
there was a leftward shift of the S-R frequency curve. This
shift of the curve suggests the presence of mechanical
hyperalgesia and allodynia since there was an increase in
response to suprathreshold stimuli and a decreased
response threshold to a level that did not in naive animals
produce a nocifensive behavior. Consistently, on the side
ipsilateral to CFA injection, the derived EF50s started to
decrease at 30 min (p < 0.01), reached its peak at 1 d (p <
0.01), and returned to the baseline level at 14 d time
points (Fig. 1A). An increased mechanical sensitivity also
developed on the contralateral side (Fig. 1B), which has
been observed previously [14]. The decrease in EF50s of
the contralateral side started at 180 min (p < 0.05), also
reached the maximum reduction at 1 d, and returned to
the baseline level at 7 d after inflammation (Fig. 1B). The
reduced EF50 on the contralateral side suggests the devel-
opment of secondary hyperalgesia after masseter inflam-
mation.
The mechanical sensitivity of the masseter muscle was
assessed through probing the overlying skin. Deep tissue
primary afferents are activated by this mechanical pres-
sure. A reduction of EF50 at the masseter testing site in
CFA-injected rats reflects tenderness and increased sensi-
tivity of deep tissue. Since cutaneous afferents may also
contribute to the pain-pressure threshold [46], this
method does not distinguish between primary muscle
hyperalgesia and referred pain to the overlying cutaneous
site. To verify muscle hyperalgesia after injection of CFA
into the masseter, we induced local anesthesia in the mas-
seter or the overlying skin ipsilateral to inflammation by
infiltrating bupivacaine (0.75%, 0.1 ml) 20 min before
injection of CFA into the masseter. Ipsilateral to CFA
injection, the hyperalgesia was eliminated when the mas-
seter was anesthetized as compared to saline-treated rats
(Fig. 1C). In contrast, the inflammation-induced hyperal-
gesia was only slightly reduced when the overlying skin
testing site was anesthetized (Fig. 1C). Thus, masseter
inflammation-induced hyperalgesia alone was detectable
when the overlying skin site was anesthetized, validating
the method for assessing the sensitivity of the masseter.
The effects of microinjection of IL-10, fluorocitrate and 
minocycline on orofacial inflammatory hyperalgesia
To administer drugs focally into the Vi/Vc transition zone
and Vc, guide cannulas were implanted. One week after
the cannulation, CFA was injected into the masseter or the
overlying skin after taking baseline responses. At 1 d after
CFA, when hyperalgesia/allodynia had peaked, drugs or
vehicle were injected into the ventral transition zone or
superficial caudal Vc ipsilateral to inflammation in a vol-
ume of 500 nl and the mechanical sensitivity reassessed.
The sections of brain stem tissues were made and stained
with cresyl violet for histological verification of the sites of
injection. We confirmed that the drugs were successfully
injected into the target sites. Examples of histological sec-
tions illustrating the injection sites in the ventral Vi/Vc
and Vc are shown in Fig. 2.
The effect of IL-10
At 1 d after injection of CFA into the masseter, EF50s were
significantly reduced bilaterally (p < 0.01) (Fig. 3A, B),
confirming the development of hyperalgesia/allodynia
(Fig. 1A, B). An antiinflammatory cytokine, IL-10, was
injected into the ventral Vi/Vc transition zone at the doses
of 0.006 ng (n = 6), 0.1 ng (n = 6) and 1.0 ng (n = 5). The
1.0 ng dose significantly attenuated hyperalgesia/allody-
nia, as shown by a significant increase in EF50s (p < 0.05)
(Fig. 3A, B). The effect of the 1.0 ng IL-10 lasted about 30-
60 min. The 0.1 ng dose only produced a significant
increase in EF50 on the contralateral side (p < 0.05) (Fig.
3B), although there was a trend to produce an increase in
EF50 on the ipsilateral side (Fig. 3A). The 0.006 ng dose
and drug vehicle saline did not affect hyperalgesia (Fig.
3A, B). IL-10 did not have any significant effect on
responses of the naive rat (Fig. 3).Molecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
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The effect of IL-10 on orofacial hyperalgesia associated with masseter inflammation Figure 3
The effect of IL-10 on orofacial hyperalgesia associated with masseter inflammation. CFA was injected into the 
right masseter muscle (M-CFA). At 24 h after CFA, there were significant decreases in the EF50 values at both ipsilateral and 
contralateral sites, confirming the development of hyperalgesia. IL-10 was injected into the Vi/Vc (A, B) or caudal Vc (C, D) in 
a volume of 500 nl after establishing behavioral hyperalgesia at 24 h after CFA (time 0). The attenuation of hyperalgesia was 
observed as a significant increase in EF50s after injection of IL-10. Note that injection of IL-10 into the Vi/Vc transition zone 
produced bilateral attenuation of hyperalgesia (A, B), injection of IL-10 into the caudal Vc only attenuated hyperalgesia ipsilater-
ally (C), and injection of IL-10 into either Vi/Vc or Vc did not produce an effect in non-inflamed (Naive) rats. Asterisks denote 
significant differences between the post-CFA (time 0) and after 1.0 ng IL-10 microinjection (p < 0.05). Pound sign denotes sig-
nificant difference between the post-CFA (time 0) and after 0.1 ng IL-10 microinjection (p < 0.05). (ANOVA with repeated-
measures and post hoc tests).
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The effect of IL-10 on orofacial hyperalgesia associated with cutaneous inflammation Figure 4
The effect of IL-10 on orofacial hyperalgesia associated with cutaneous inflammation. CFA was injected into the 
skin site overlying the right masseter muscle (S-CFA). At 24 h after CFA (time 0), there were significant decreases in the EF50 
values ipsilateral to CFA injection (A, C), confirming the development of inflammatory hyperalgesia. There was no hyperalgesia 
developed at the contralateral site (B, D). IL-10 (1.0 ng) was injected into the Vi/Vc (A, B) or caudal Vc (C, D) in a volume of 
500 nl after establishing behavioral hyperalgesia at 24 h after CFA. The attenuation of hyperalgesia was observed as a significant 
increase in EF50s after injection of IL-10. Injection of IL-10 into the Vi/Vc transition zone (A) did not attenuate cutaneous 
hyperalgesia. Injection of IL-10 into the caudal Vc (C) attenuated hyperalgesia, compared to saline (vehicle)-injected rats. Injec-
tion of IL-10 into either Vi/Vc or Vc did not produce an effect in non-inflamed (Naive) rats. Asterisks denote significant differ-
ences between the post-CFA (time 0) and after 1.0 ng IL-10 microinjection (p < 0.01). (ANOVA with repeated-measures and 
post hoc tests).
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The injection of IL-10 (1.0 ng) into the superficial caudal
Vc significantly attenuated hyperalgesia on the ipsilateral
side 30-60 min after IL-10 injection (p < 0.05) (Fig. 3C)
when compared to saline control. However, this dose of
IL-10 did not attenuate hyperalgesia on the contralateral
side (Fig. 3D).
To compare the effect of IL-10 on masseter hyperalgesia
versus cutaneous hyperalgesia, we injected CFA unilater-
ally into the skin side overlying the masseter to produce
cutaneous inflammation and hyperalgesia. Cutaneous
inflammation was only associated with hyperalgesia on
the ipsilateral side and was assessed 1 d after CFA (Fig. 4).
Injection of IL-10 (1.0 ng) into the ventral Vi/Vc did not
attenuate cutaneous hyperalgesia (Fig. 4A). However,
The effect of fluorocitrate on CFA-induced orofacial hyperalgesia Figure 5
The effect of fluorocitrate on CFA-induced orofacial hyperalgesia. CFA was injected into the right masseter muscle 
(Masseter-CFA, A-D) or into the right cutaneous site overlying masseter muscle (S-CFA, E, F). Masseter inflammation was 
associated with bilateral hyperalgesia and only ipsilateral hyperalgesia was seen after cutaneous inflammation, tested at 24 h 
after inflammation immediately before the injection of the drug. Fluorocitrate (FC, 1.0 μg) was injected into the Vi/Vc (A, B) or 
caudal Vc (C-F) in a volume of 500 nl after establishing behavioral hyperalgesia at 24 h after CFA. The attenuation of hyperalge-
sia was observed as a significant increase in EF50s. Injection of fluorocitrate into the Vi/Vc transition zone attenuated hyperalge-
sia bilaterally after masseter CFA (A, B). Injection of fluorocitrate into the caudal Vc only attenuated masseter hyperalgesia on 
the ipsilateral site (C) and without an effect on contralateral hyperalgesia (D), compared to saline (vehicle)-injected rats. Injec-
tion of fluorocitrate into the caudal Vc attenuated cutaneous hyperalgesia (E) and without an effect on the contralateral side 
(F). Injection of fluorocitrate into either Vi/Vc or Vc did not produce an effect in non-inflamed (Naive) rats. Asterisks denote 
significant differences between the post-CFA (time 0) and after 1.0 ng IL-10 microinjection (*, p < 0.05; **, p < 0.01). (ANOVA 
with repeated-measures and post hoc tests).
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injection of the same dose of IL-10 into the caudal super-
ficial Vc significantly increased EF50s, or reversed hyperal-
gesia, at 10 min after IL-10 (p < 0.01, n = 5) (Fig. 4C).
Effect of fluorocitrate
We have shown recently that injection of a gliotoxin,
fluorocitrate, into the ventral Vi/Vc transition zone pro-
duced dose-dependent attenuation of masseter hyperalge-
sia and inhibition of NMDA receptor phosphorylation
after inflammation [17]. In the present study, at 1 d after
injecting CFA into the masseter muscle, the attenuation of
hyperalgesia was produced by focal microinjection of
fluorocitrate (1.0 μg) into the ventral Vi/Vc transition
zone or in the Vc via a chronically implanted guide can-
nula. Compared with post-CFA, the reductions in EF50s
were reversed on the ipsilateral site starting at 30 min and
lasting for 60 min after the fluorocitrate injection (1.0 μg;
n = 5) into the ipsilateral Vi/Vc (Fig. 5A). The reversal of
The effect of minocycline on CFA-induced orofacial hyperalgesia Figure 6
The effect of minocycline on CFA-induced orofacial hyperalgesia. CFA was injected into the right masseter muscle 
(Masseter-CFA, A-D) or into the right cutaneous site overlying masseter muscle (S-CFA, E). Masseter inflammation was asso-
ciated with bilateral hyperalgesia and only ipsilateral hyperalgesia was seen after cutaneous inflammation, tested at 24 h after 
inflammation immediately before the injection of the drug. Minocycline (MC) was injected into the Vi/Vc (A, B) or caudal Vc 
(C-E) in a volume of 500 nl after establishing behavioral hyperalgesia at 24 h after CFA. The attenuation of hyperalgesia was 
observed as a significant increase in EF50s. Injection of minocycline into the Vi/Vc transition zone attenuated hyperalgesia bilat-
erally after masseter CFA (A, B). Injection of fluorocitrate into the caudal Vc only attenuated masseter hyperalgesia on the ipsi-
lateral site (C) and without an effect on contralateral hyperalgesia (D). Injection of minocycline into the caudal Vc attenuated 
cutaneous hyperalgesia (E). Injection of minocycline into either Vi/Vc or Vc did not produce an effect in non-inflamed (Naive) 
rats. Asterisks denote significant differences between the post-CFA (time 0) and after 1.0 μg minocycline microinjection (*, p < 
0.05; **, p < 0.01). Pound sign denotes significant difference between the post-CFA and after 0.1 μg minocycline microinjection 
(p < 0.05). (ANOVA with repeated-measures and post hoc tests).
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reduction in EF50s on the contralateral site was significant
60-90 min after fluorocitrate microinjection (1.0 μg; n =
5) into the ipsilateral Vi/Vc (Fig. 5B). On the other hand,
the reduction in EF50s on the ipsilateral site, but not con-
tralateral site, was significantly reversed at 30 min after
fluorocitrate microinjection (1.0 μg; p < 0.05, n = 5) into
the ipsilateral Vc, compared to post-CFA (Fig. 5C, D). At 1
d after injecting CFA into the cutaneous site, hyperalgesia
developed ipsilaterally, but not contralaterally (Fig. 5E, F).
The attenuation of cutaneous hyperalgesia was observed
30-60 min after injection of fluorocitrate (1.0 μg, p < 0.05,
n = 5) into the Vc, whereas intra-Vi/Vc fluorocitrate did
not produce an effect (1.0 μg, n = 5) (data not shown).
Effect of minocycline
Minocycline, a semisynthetic tetracycline, is an inhibitor
of microglial activation and apparently has no direct
action on astrocytes or neurons [47,48]. At 1 d after inject-
ing CFA into the masseter  muscle, the attenuation of
hyperalgesia was observed after focal microinjection of
minocycline (0.1 and 1.0 μg, n = 6/dose) into the ventral
Vi/Vc transition zone. Compared with post-CFA values,
the reduction in EF50s on the ipsilateral site was signifi-
cantly reversed at 30 min (0.1 μg, p < 0.05 and 1.0 μg, p <
0.01) and 60 min (1.0 μg, p < 0.01) after minocycline
injection (0.1 and 1.0 μg) into the ipsilateral Vi/Vc (Fig.
6A). The reduction in EF50s on the contralateral site was
significantly reversed at 60 min after minocycline injec-
tion (1.0 μg, p < 0.01) into the Vi/Vc (Fig. 6B). On the
other hand, after injection of minocycline (1.0 μg, n = 6)
into the ipsilateral Vc, the reduction in EF50s on the ipsi-
lateral, but not contralateral site, was significantly
reversed at 60-90 min (Fig. 6C, D). At 1 d after injection
of CFA into the cutaneous site, the attenuation of hyperal-
gesia was observed after injection of minocycline (1.0 μg)
into the ipsilateral Vc (Fig. 6E), while intra-Vi/Vc minocy-
cline did not produce an effect (1.0 μg; n = 6, data not
shown).
Taken together (Table 1), microinjection of the antiin-
flammatory cytokine, IL-10, or glial inhibitors, fluoroci-
trate or minocycline, into the Vi/Vc transition zone
attenuated orofacial hyperalgesia bilaterally after masseter
inflammation. On the other hand, injection of these drugs
into the superficial caudal Vc produced only ipsilateral
attenuation of hyperalgesia after masseter inflammation.
In contrast, cutaneous inflammation-induced orofacial
hyperalgesia was attenuated by injecting IL-10, fluoroci-
trate and minocycline into the Vc but not the Vi/Vc site.
Finally, these drugs had no effect on baseline responses of
the non-inflamed (naive) rats.
The effects of microinjection of IL-10, fluorocitrate and 
minocycline on IL-1β mRNA transcription
We have shown previously that in response to masseter
inflammation, there was a time-dependent upregulation
of IL-1β, a prototype proinflammatory cytokine, in the
trigeminal transition zone [17]. We next examined
Table 1: Summary of the effects of microinjection of IL-10, fluorocitrate and minocycline into the Vi/Vc or caudal Vc zone on CFA-
induced masseter or cutaneous hyperalgesia.
IL-10 Fluorocitrate Minocycline Saline
Vi/Vc Vc Vi/Vc Vc Vi/Vc Vc Vi/Vc Vc
Masseter-CFA
Ipsilateral + + + + + + - -
Contralateral + - + - + - - -
Skin-CFA
Ipsilateral - + - + - + - -
Contralateral - - - - - - - -
Naive
Ipsilateral - - - - - - - -
Contralateral - - - - - - - -
Plus signs (+) indicate significant attenuation of hyperalgesia. Minus signs (-) indicate a lack of effect on hyperalgesia. Note that intra-Vi/Vc injection 
of the three agents attenuated bilateral hyperalgesia associated with masseter inflammation without an effect on cutaneous hyperalgesia. Intra-Vc 
injection of the three agents only attenuated ipsilateral hyperalgesia after both masseter and cutaneous inflammation.Molecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
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whether the effect of IL-10 and glial inhibitors on behav-
ioral hyperalgesia was associated with an inhibition on IL-
1β expression, a chemical mediator of inflammatory
hyperalgesia in the Vi/Vc transition zone. Since the in vivo
elimination half-life of IL-1β in rats is about 40 min [49],
it is unlikely that a down-regulation of the existing IL-1β
at the protein level would be detectable at the time when
antihyperaglesic effect of the inhibitors occurred at 30-60
min after administration. Thus, we studied IL-1β mRNA
transcription by RT-PCR.
Following the same surgery and inflammation procedure
as in the above behavioral experiment, Vi/Vc tissues were
taken out at 30-60 min after microinjection of IL-10 (1.0
ng, n = 6), fluorocitrate (1.0 μg, n = 6) or minocycline (1.0
μg, n = 6) into the Vi/Vc transition zone. The primers used
in this experiment targeted a 448-b segment of IL-1β
mRNA (Table 2). Relative mRNA levels were compared
after RT-PCR reactions. Masseter muscle inflammation
induced a significant upregulation of IL-1β mRNA at 24 h
after injection of CFA (p < 0.01) (Fig. 7). Compared to
vehicle saline-injected rats (A, n = 6; B, n = 7), the IL-1β
Table 2: Polymerase chain reaction primers
Gene Accession No./Positions Sense/Antisense Sequences Product (bp)
GAPDH X02231/76-101 Sense TGA AGG TCG GTG TGA ACG GAT TTG GC 983
X02231/1058-1035 Antisense CAT GTA GGC CAT GAG GTC CAC CAC
IL-1β NM_031512/345-364 Sense GCA CCT TCT TTT CCT TCA TC 448
NM_031512/792-773 Antisense CTG ATG TAC CAG TTG GGG AA
Agarose gel electrophoresis (upper panel, two experiments) and quantitative comparison (lower panel) of RT-PCR-amplified  products of the IL-1β mRNAs from rat Vi/Vc tissues Figure 7
Agarose gel electrophoresis (upper panel, two experiments) and quantitative comparison (lower panel) of RT-
PCR-amplified products of the IL-1β mRNAs from rat Vi/Vc tissues. A. Effect of IL-10. B. Effect of fluorocitrate (FC) 
and minocycline (MC). Compared to naive controls (N), there were significant increases in IL-1β mRNAs in the Vi/Vc transi-
tion zone after CFA-induced masseter inflammation, which was reversed in rats receiving IL-10, FC or MC. Asterisks denote 
significant differences from CFA or Sal-CFA, **, P < 0.01. Error bars represent S.E.M.Molecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
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levels were reduced to the control level after injection of
IL-10 (Fig. 7A), fluorocitrate or minocycline (Fig. 7B) into
Vi/Vc.
Effects of masseter and skin inflammation on NMDA 
receptor phosphorylation and GFAP protein levels
To verify differential involvement of the trigeminal Vi/Vc
transition zone and caudal laminated Vc in response to
deep or cutaneous orofacial tissue injury, we examined
NMDA receptor phosphorylation and upregulation of
GFAP, a marker of reactive astrocytes after masseter and
cutaneous inflammation. NMDA receptors are promi-
nently involved in persistent pain and exhibit enhanced
subunit phosphorylation after injury [50-52]. We have
shown that masseter inflammation induced a significant
increase in NMDA receptor NR1 subunit phosphorylation
Western blots illustrating enhanced NMDA receptor phosphorylation and upregulation of GFAP levels in the trigeminal Vi/Vc  transition zone and caudal Vc after masseter or skin inflammation Figure 8
Western blots illustrating enhanced NMDA receptor phosphorylation and upregulation of GFAP levels in the 
trigeminal Vi/Vc transition zone and caudal Vc after masseter or skin inflammation. The examples of immunoreac-
tive bands for phosphoserine896 NR1 subunit (P-NR1) of the NMDA receptor (A) and GFAP (B) are shown on top of each 
panel. CFA was injected into the masseter (Masseter-CFA) or the overlying skin site (Skin-CFA) to produce deep or cutaneous 
inflammation, respectively. Note that compared to naive and saline controls, masseter inflammation induced an increase in P-
NR1 and GFAP levels in both Vi/Vc and caudal Vc at 30 min (30') and 24 h after CFA (Left). However, cutaneous inflammation 
only led to an increase in P-NR1 and GFAP levels in caudal Vc, but not in Vi/Vc transition zone (Right). *, p < 0.05; **, p < 0.01 
vs. naive rats. N = 3-4 for each time point. Error bars represent S.E.M.Molecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
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and GFAP levels in the Vi/Vc transition zone [17]. Injec-
tion of the NMDA receptor antagonist into the Vi/Vc tran-
sition zone attenuated orofacial hyperalgesia after
masseter inflammation [7]. Here we compared the effects
of masseter inflammation with that of inflammation of
the skin site overlying the masseter muscle. As shown in
Fig. 8, injection of CFA into the masseter produced signif-
icant increases in NR1 serine 896 phosphorylation (Fig.
8A left) and GFAP levels (Fig. 8B left) in both Vi/Vc and
caudal Vc. In contrast, injection of CFA into the cutaneous
site only produced an increase in NMDA receptor phos-
phorylation (Fig. 8A right) and GFAP (Fig. 8B right) levels
in the Vc without an effect in Vi/Vc.
Discussion
The aims of the present study were two-fold. First, we
examined the effects of antiinflammatory cytokine and
glial inhibitors on orofacial hyperalgesia following focal
microinjection into the subregions of the spinal trigemi-
nal complex. Second, we further established the role of
the trigeminal Vi/Vc transition zone in the development
of hyperalgesia associated with deep tissue injury. After
systematic comparison, it is clear that injection of an anti-
inflammatory cytokine, IL-10, and two glial inhibitors,
fluorocitrate and minocycline, into the Vi/Vc transition
zone attenuated hyperalgesia after masseter muscle
inflammation, but had no effect on hyperalgesia after
cutaneous inflammation. On the other hand, injection of
these agents into the caudal Vc attenuated hyperalgesia
associated with both masseter and cutaneous inflamma-
tion. Western blot data showed that masseter inflamma-
tion induced an enhanced NMDA receptor
phosphorylation and upregulation of GFAP in both Vi/Vc
and Vc zones, while cutaneous inflammation only
induced similar effects in the caudal Vc. These findings
support the view that glial activation and cytokine activity
are important factors in persistent pain development and
the Vi/Vc transition zone provides additional processing
for deep orofacial input.
Cytokines are a complex group of proteins able to exert
pleiotropic effects on activity of a variety of cells. Together
with a group of so-called proinflammatory cytokines includ-
ing tumor necrosis factor (TNF), IL-1, IL-6 and IL-8, a vari-
ety of antiinflammatory cytokines including IL-10 and the
IL-1 receptor antagonist (IL-1ra) are also produced during
humoral and cell-mediated immune responses [53].
Interleukin-10 is induced in the CNS in a number of dis-
ease conditions [54]. Analysis of cytokine mRNA expres-
sion in the CNS of mice with experimental autoimmune
encephalomyelitis reveals that IL-10 mRNA expression
correlates with recovery [55].
Interleukin-10 acts on immune cells to suppress the
release of IL-1 and TNF-α [56]. Interleukin-1ra, an ana-
logue of IL-1, antagonizes IL-1 activity by competing for
IL-1 receptors. We have previously shown that IL-1ra
attenuated inflammation-induced NMDA receptor phos-
phorylation and hyperalgesia [17,57]. The present study
further found that IL-10 produced antihyperalgesia and
inhibition of IL-1β transcription in a rat model of orofa-
cial inflammatory pain when injected into the identified
brain stem sites involved in trigeminal pain processing.
These results are consistent with the antinociceptive and
neuroprotective effects of IL-10 at the spinal level and sup-
port the use of IL-10 as a therapeutic agent against persist-
ent pain [34,35,58-60].
The use of two glial inhibitors in the present study pro-
duced attenuation of orofacial hyperalgesia. These obser-
vations are consistent with the literature [61-63].
Minocycline selectively inhibits microglia [47,48]. Fluor-
ocitrate has been shown to be relatively selective against
astroglia [19,64]. Our results support the current view that
central glial activation plays a role in orofacial hyperalge-
sia [17,19,20] or persistent pain in general [22]. It appears
that the involvement of glia occurred at multiple levels
since the injection of glial inhibitors into the two subre-
gions of the spinal trigeminal complex was effective in
attenuating hyperalgesia. Evidence suggests that glia are
intimately involved in the control of neuronal activity
[65,67]. Glial TNF-α modulates synaptic strength in the
brain [68,69]. However, the functional consequence of
glial activation is not fully understood. Models of periph-
eral nerve injury and neuropathic pain have been associ-
ated with a decrease in astrocytic glutamate transporter
activity [70-73] and astroglia are apparently activated in
response to peripheral nerve or tissue injury [17,74].
Thus, there is a reciprocal relationship between the astro-
cytic activation state after nerve injury and astrocytic gluta-
mate transporter GLT-1 expression. In primary astrocytic
cultures that exhibit an activated phenotype, propentofyl-
line, a glial modulator, induces glutamate transporter
GLT-1 expression and glutamate uptake [75]. Since astro-
glial glutamate transporters play an important role in
maintaining an appropriate level of glutamate extracellu-
lar concentration, a reduction in GLT-1 glutamate trans-
porter expression may lead to a build up of glutamate
concentration in the synaptic cleft, resulting in neuronal
hyperexcitability and behavioral hyperalgesia.
After masseter inflammation, IL-1β is selectively induced
in astroglia in the Vi/Vc region [17], although previous
studies have indicated that IL-1β is produced primarily in
microglia [76]. It is interesting that both glial inhibitors
suppressed inflammation-induced IL-1β mRNA upregula-
tion. These results suggest interaction between microglia
and astroglia in the mechanisms of inflammatory hyper-
algesia. Studies have suggested that microglial activation
precedes activation of astrocytes [see [18], for a review].Molecular Pain 2009, 5:75 http://www.molecularpain.com/content/5/1/75
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Activation of TLR4 on microglial cells may lead to astro-
glial activation [77]. Kawasaki et al. [78] showed that early
microglial and later astroglial activation were associated
with neuropathic pain. Recent studies suggest that IL-18,
a member of the IL-1 cytokine family, is released from
microglia and acts on the IL-18 receptor on astrocytes
[79]. The IL-18-mediated microglia-astroglia interaction
potentiates neuropathic pain behavior in rats; and inhibi-
tion of IL-18 signaling pathways suppresses astroglial
activity and nerve injury-induced allodynia [79]. Taken
together, these findings support the view that coordinated
activation of microglia and astroglia contribute to the
development and maintenance of persistent pain.
The present study showed that orofacial inflammatory
hyperalgesia was attenuated by injection of an antiinflam-
matory cytokine and two glial inhibitors into the spinal
trigeminal complex, associated with a reduction of IL-1β
mRNAs. However, these drugs did not produce an effect
on baseline responses before inflammation, suggesting
that cytokine and glial activity do not contribute to pain
processing under normal conditions. While these data
support the involvement of both glia and inflammatory
cytokines in persistent pain, the mechanisms of interac-
tions between IL-10 and glia during the pain processing
are only speculative. Interleukin-10 not only inhibits syn-
thesis of proinflammatory cytokines by macrophages/
microglia, it also induces anergy in brain-infiltrating T
cells [54]. The activation of astroglia may be suppressed
by IL-10 indirectly through inhibition of cytokine produc-
tion [80]. We have shown recently that astroglial activa-
tion and IL-1β upregulation in the Vi/Vc transition zone
contributes to trigeminal responses to deep orofacial tis-
sue inflammation and hyperalgesia [17]. The inhibition
of IL-1β mRNA transcription by IL-10 and glial inhibitors
would be consistent with their antihyperalgesic effect.
Importantly, IL-10 suppresses p38 mitogen-activated pro-
tein kinase activation in immune cells [81], which may be
a key interface between IL-10 and glial cells in producing
antihyperalgesia [see [56]].
Through a systematic comparison of the effects of IL-10,
fluorocitrate and minocycline on masseter and cutaneous
hyperalgesia, we further demonstrate a selective involve-
ment of the trigeminal Vi/Vc transition zone in response
to deep orofacial tissue injury. Injection of these agents
into the Vi/Vc transition zone only attenuated hyperalge-
sia after masseter inflammation without an effect on cuta-
neous hyperalgesia. In contrast, both masseter and
cutaneous hyperalgesia were attenuated after injection of
these agents into the caudal Vc, which is consistent with a
role of laminated Vc in trigeminal pain processing. These
results are in good agreement with our previous study
where an NMDA receptor antagonist was injected [7].
These observations are further supported by Western blot
analysis that shows a selective enhancement of NMDA
receptor phosphorylation and GFAP upregulation in the
Vi/Vc transition zone after masseter inflammation. The
findings strengthen the view that while both deep and
cutaneous orofacial nociceptive input are processed in the
laminated Vc, the trigeminal Vi/Vc transition zone is also
involved in integrating responses to deep tissue injury
[82].
One important feature of neuronal activation in the Vi/Vc
transition zone is that a unilateral injury always produces
bilateral activation, particularly in the ventral Vi/Vc
[8,10,1,13]. This is in sharp contrast to caudal laminated
Vc where a predominantly unilateral neuronal activation
is always observed [11]. Interestingly, contralateral as well
as ipsilateral hyperalgesia developed after a unilateral
injection of CFA into the masseter. In contrast, unilateral
cutaneous inflammation only produced hyperalgesia on
the ipsilateral side. It appears that contralateral Vi/Vc acti-
vation underlies the development of contralateral hyper-
algesia, which should be categorized as secondary
hyperalgesia or pain referred to a site remote from the
injury. We also observed for the first time that unilateral
administration of IL-10, fluorocitrate or minocycline into
the Vi/Vc transition zone was able to attenuate ipsilateral,
as well as contralateral, hyperalgesia after masseter
inflammation. These results suggest an indirect or polysy-
naptic circuitry from the ipsilateral to the opposite Vi/Vc.
An important relay is likely in the rostral ventromedial
medulla (RVM), the pivotal structure in descending pain
modulation including inhibition and facilitation [83].
Sugiyo et al. [14] have shown a reciprocal pain facilitatory
circuitry between the RVM and Vi/Vc transition zone.
Lesions of the RVM eliminate masseter hyperalgesia on
both sides [14]. Neuronal activation in the Vi/Vc is also
modulated by input from the caudal Vc [14,84-86]. How-
ever, injection of either one of the three drugs into the Vc
only reduced ipsilateral hyperalgesia without an effect on
contralateral hyperalgesia. This would suggest that, with
regard to secondary hyperalgesia, facilitation from the
RVM-Vi/Vc circuitry is sufficient and necessary.
Conclusion
These findings support the view that glial activation and
cytokine activity are important factors in persistent pain
development and the Vi/Vc transition zone provides addi-
tional processing for deep orofacial input. The glial inhi-
bition and interruption of the cytokine cascade after
inflammation may provide pain relief.
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